发文地区与机构
近年国家 / 地区发文量统计
| 国家 / 地区 | 发文量 |
|---|---|
| USA | 239 |
| Japan | 55 |
| CHINA MAINLAND | 53 |
| England | 42 |
| GERMANY (FED REP GER) | 23 |
| Canada | 20 |
| Switzerland | 20 |
| Netherlands | 10 |
| South Korea | 10 |
| France | 9 |
近年机构发文量统计
| 机构 | 发文量 |
|---|---|
| GLAXOSMITHKLINE | 39 |
| PFIZER | 34 |
| MERCK & COMPANY | 24 |
| ASTRAZENECA | 12 |
| ABBVIE | 10 |
| ASTELLAS PHARMACEUTICALS | 9 |
| JOHNSON & JOHNSON | 9 |
| PAREXEL INT | 8 |
| ROCHE HOLDING | 8 |
| NOVARTIS | 7 |
文章引用情况
1
Effect of a High-Fat Meal on the Pharmacokinetics of the HIV Integrase Inhibitor Cabotegravir2
Clinical Bioavailability of the Novel BACE1 Inhibitor Lanabecestat (AZD3293): Assessment of Tablet Formulations Versus an Oral Solution and the Impact of Gastric pH on Pharmacokinetics3
A Pharmacokinetic Study of an Ibuprofen Topical Patch in Healthy Male and Female Adult Volunteers4
Pharmacokinetics and Pharmacodynamics of Luseogliflozin, a Selective SGLT2 Inhibitor, in Japanese Patients With Type 2 Diabetes With Mild to Severe Renal Impairment5
Pharmacokinetics, Safety, Tolerability, and Pharmacodynamics of Alicapistat, a Selective Inhibitor of Human Calpains 1 and 2 for the Treatment of Alzheimer Disease: An Overview of Phase 1 Studies6
Evaluation of Food and Spherical Carbon Adsorbent Effects on the Pharmacokinetics of Roxadustat in Healthy Nonelderly Adult Male Japanese Subjects7
Bioequivalence of Two Formulations of Gliclazide in a Randomized Crossover Study in Healthy Caucasian Subjects Under Fasting Conditions8
A Thorough QT/QTc Study With Laquinimod, a Novel Immunomodulator in Development for Multiple Sclerosis and Huntington Disease9
Characterizing the Sources of Pharmacokinetic Variability for TAK-117 (Serabelisib), an Investigational Phosphoinositide 3-Kinase Alpha Inhibitor: A Clinical Biopharmaceutics Study to Inform Development Strategy10
Pharmacokinetics of Co-Suspension Delivery Technology Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate (BGF MDI) and Budesonide/Formoterol Fumarate Dihydrate (BFF MDI) Fixed-Dose Combinations Compared With an Active Control: A Phase Randomized, Single-Dose, Crossover Study in Healthy Adults